Australian real-world outcomes of ribociclib and aromatase inhibitor in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): Results from Kisqali Access Registry for Metastatic breast cancer in Australia (KARMA) collected alongside a medicine access program.

Vanessa Wong,Richard de Boer,Sally Baron-Hay,Robert Blum,Benjamin Forster,Susan Li Ling Chua,Katharine Cuff,Michael F. Green,Elgene Lim,Kelly Mok,Louise M. Nott,Michelle K. Nottage,Ali Tafreshi,Daphne Tsoi,Belinda Yeo,Peter Gibbs,Sheau Wen Lok

Australian real-world outcomes of ribociclib and aromatase inhibitor in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): Results from Kisqali Access Registry for Metastatic breast cancer in Australia (KARMA) collected alongside a medicine access program.

2021

Vanessa Wong
Richard de Boer
Sally Baron-Hay
Robert Blum
Benjamin Forster
Susan Li Ling Chua
Katharine Cuff
Michael F. Green
Elgene Lim
Kelly Mok
Louise M. Nott
Michelle K. Nottage
Ali Tafreshi
Daphne Tsoi
Belinda Yeo
Peter Gibbs
Sheau Wen Lok

e13018Background: International guidelines recommend a combination of CDK4/6 inhibitor and endocrine therapy (ET) as first line treatment for HR+, HER2- MBC. Results from MONALEESA-2 demonstrate im...

Keywords:

Medicine
Ribociclib
Internal medicine
Aromatase inhibitor
Oncology
Hormone receptor
Metastatic breast cancer
Karma
HER2 negative
first line treatment
real world outcomes

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations